New Search

If you are not happy with the results below please do another search

34 search results for: amed


Amedisys: Caught Between a RAC and a Hard Place

Citron first reported on Amedisys over a year ago.  Never before have we received as much correspondence from former employees as we did after this story.  Last month, the market witnessed the abrupt resignations of two key executives from Amedisys.  In this post, Citron will shed some light on the “story behind the story” of […]


Seeking Healthy Returns in Amedisys? (NASDAQ:AMED)

Better get a Second Opinion…. Citron Research was first drawn to research Arthrocare because one division was running margins that wildly outperformed all their competitors.  After working countless hours with private investigators and reviewing hundreds of documents, we were able to draw a line to what we believe explained the extreme outperformance:  fraud on the […]